The first JAK inhibitor, Xeljanz (Tofacitinib), was approved for use by the FDA for rheumatoid arthritis use in 2012. It was a breakthrough medication for RA as it was the first to offer a targeted drug in pill form
I wrote this in 2014 about having cancer. My rheumatologist was responsible for finding my three cancers.
Polymyalgia rheumatica is a disease of the elderly that can cause great difficulty in managing day to day activities.
The reality is that the biologics do not relieve the RA symptoms for most of us. You only have to read the drug inserts to understand why.
With Shingrix you will less likely have Shingles and less likely have neuro complications caused by the varicella zoster virus.